Clinical trial
A Double-blind, Randomized, Placebo-controlled, Multicenter, Fixed Dose Titration Study to Assess Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
NCT01124708 is registered in ClinicalTrials.gov with Targacept Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-blind, Randomized, Placebo-controlled, Multicenter, Fixed Dose Titration Study to Assess Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
- Lead sponsor
- Targacept Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 2010
- Completion date
- February 28, 2011
- Enrollment
- 134 (actual)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.
adhd